Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2023 Earnings Call Transcript

Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2023 Results Conference Call August 2, 2023 8:00 AM ET

Company Participants

Matthew Calistri - Vice President of Investor Relations
Ron Renaud - President and Chief Executive Officer
Raymond Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Susan Altschuller - Interim Chief Financial Officer

Conference Call Participants

Michael DiFiore - Evercore ISI
Mohit Bansal - Wells Fargo
Graig Suvannavejh - Mizuho Securities
Tazeen Ahmad - Bank of America
Paul Matteis - Stifel
Joseph Thome - TD Cowen
Jeff Hung - Morgan Stanley
Michael Yee - Jefferies
Charles Duncan - Cantor Fitzgerald
Douglas Tsao - H.C. Wainwright

Operator

Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded.

I will now hand the call over to Matt Calistri, Vice President of Investor Relations.

Matthew Calistri

Thank you. Good morning, everyone. We appreciate you joining us for our second quarter 2023 earnings call. On today’s call, you will be hearing from Dr. Ron Renaud, our President and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Susan Altschuller, our Interim Chief Financial Officer.

During our call today, please refer to our press release from this morning, detailing our second quarter 2023 performance, as well as our updated corporate presentation, both of which are available on our website.

I would like to remind you that, we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical